In June 2021, The Food and Drug Administration (FDA) approved semaglutide for the treatment of overweight with at least one weight-related condition such as diabetes, high blood pressure or high cholesterol and obesity
Rates of treatment discontinuationmost commonly from gastrointestinal symptomswere higher, at 6 to 10 percent, depending on the dose, for those who received the pill, compared with a rate of 4 percent for those who received the placebo
If side effects occur, your healthcare provider might extend this phase by an additional four weeks to ensure comfort and safety
Milkshake frozen banana blended with skimmed milk Milkshakes contain high fat and sugar, again spiking blood sugar and slowing down digestion
Schloot, et al., 'Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial', Lancet Diabetes Endocrinol
PLoS ONE 8 , e69010 (2013)